Cell death by apoptosis and permanent cell cycle arrest by senescence serve as barriers to
the development of cancer. Chemotherapeutic agents not only induce apoptosis, they can …

Abstract MCL1 (myeloid cell leukemia-1) is a widely recognized pro-survival member of the
Bcl-2 (B-cell lymphoma protein 2) family and a promising target for cancer therapy. While the …

Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …

Abstract The mammalian SWItch/Sucrose Non-Fermentable (SWI/SNF) helicase SMARCA4
is frequently mutated in cancer and inactivation results in a cellular dependence on its …

Simple Summary CDK9, in combination with Cyclin T1, is one of the major regulators of RNA
Polymerase II mediated productive transcription of critical genes in any cell. The activity of …

Background MCL-1 is a prosurvival B-cell lymphoma 2 family protein that plays a critical role
in tumor maintenance and survival and can act as a resistance factor to multiple anticancer …

Abstract Cyclin-dependent kinase 9 (CDK9) activity is correlated with worse outcomes of
triple-negative breast cancer (TNBC) patients. The heterodimer between CDK9 with cyclin …

Abstract Treatment options for the management of breast cancer are still inadequate. This
inadequacy is attributed to the lack of effective targeted medications, often resulting in the …

Acute myeloid leukemias (AML) are a group of aggressive hematologic malignancies
resulting from acquired genetic mutations in hematopoietic stem cells that affect patients of …

Therapeutic developments targeting acute myeloid leukemia (AML) have been in the
pipeline for five decades and have recently resulted in the approval of multiple targeted …